Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline.

This document is a guideline from the British Society for Haematology on the diagnosis and management of mantle cell lymphoma (MCL). It provides healthcare professionals with clear guidance on how to diagnose and treat patients with MCL. The guideline includes a literature review of relevant studies and recommendations based on the evidence. It covers topics such as pretreatment evaluation, initial clinical assessment, staging, and prognostic models for MCL. The document also includes diagnostic features of MCL and information on frailty assessments and prognostication models. The text discusses the use of different prognostic indices and treatment recommendations for mantle cell lymphoma (MCL). It mentions the use of the Mantle Cell Lymphoma International Prognostic Index (MIPI) and its simplified version (s-MIPI) for risk stratification. It also introduces the biological MIPI (MIPI-B) score, which incorporates Ki-67, and the combined MIPI (MIPI-C) score. The text provides recommendations for clinical assessment, diagnostic tests, and treatment options for MCL patients. It also discusses the use of radiotherapy and observation for early-stage MCL, as well as the use of intensive chemotherapy induction followed by autologous stem cell transplantation (ASCT) for younger patients. The text emphasizes the importance of rituximab maintenance therapy after ASCT. The text discusses various treatment options for mantle cell lymphoma (MCL) based on different patient profiles and disease characteristics. It emphasizes [Extracted from the article]